<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426865</url>
  </required_header>
  <id_info>
    <org_study_id>STU 032017-051</org_study_id>
    <nct_id>NCT03426865</nct_id>
  </id_info>
  <brief_title>Role of Axumin PET Scan in Germ Cell Tumor</brief_title>
  <acronym>TESTPET</acronym>
  <official_title>Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will use Axumin PET/CT to help with the imaging modalities to determine the&#xD;
      presence of occult retroperitoneal disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators aim to perform a prospective study of anti-18F-FACBC PET/CT in patients with&#xD;
      NSGCT prior to RPLND, either in the primary setting or in the post-chemotherapy setting. We&#xD;
      will correlate histopathologic outcomes from the RPLND specimen and clinical outcomes of&#xD;
      recurrence during follow-up to identify the accuracy of anti-18F-FACBC PET/CT in these&#xD;
      settings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance characteristics of Axumin PET scan in patients undergoing retroperitoneal lymph node dissection</measure>
    <time_frame>Two years</time_frame>
    <description>Investigate the accuracy of anti-18F-FACBC PET/CT correlating with histopathologic outcomes</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Testis Cancer</condition>
  <condition>Germ Cell Tumor</condition>
  <condition>Testicular Cancer</condition>
  <condition>Germ Cell Tumor of Testis</condition>
  <condition>Germ Cell Tumor, Testicular, Childhood</condition>
  <condition>Testicular Neoplasms</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <condition>Testicular Yolk Sac Tumor</condition>
  <condition>Testicular Choriocarcinoma</condition>
  <condition>Testicular Diseases</condition>
  <condition>Germ Cell Cancer Metastatic</condition>
  <condition>Germ Cell Neoplasm of Retroperitoneum</condition>
  <condition>Germ Cell Cancer, Nos</condition>
  <arm_group>
    <arm_group_label>Axumin PET scan</arm_group_label>
    <description>Only one arm is being evaluated--the arm receiving PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axumin PET scan</intervention_name>
    <description>PET scan prior to RPLND</description>
    <arm_group_label>Axumin PET scan</arm_group_label>
    <other_name>PET SCAN ARM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population will be selected from patients seen in the clinic at University of Texas&#xD;
        Southwestern Medical Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to&#xD;
             undergo primary RPLND or post-chemotherapy RPLND&#xD;
&#xD;
          -  Patients must be over 18 years old and capable and willing to provide informed&#xD;
             consent.&#xD;
&#xD;
          -  Medically stable as judged by patient's physician.&#xD;
&#xD;
          -  Life expectancy must be estimated at &gt; 6 months.&#xD;
&#xD;
          -  Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age&#xD;
             &gt;70 years).&#xD;
&#xD;
          -  Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be&#xD;
             asked if they have problems or issues with lying flat&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known allergic or hypersensitivity reactions to previously administered&#xD;
             radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are&#xD;
             NOT eligible.&#xD;
&#xD;
          -  Patients with liver failure are NOT eligible.&#xD;
&#xD;
          -  Patients currently undergoing chemotherapy or chemotherapy within two weeks of&#xD;
             anti-18F-FACBC PET/CT scan are NOT eligible&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males with germ cell tumors (testicular cancer)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yair Lotan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Yair Lotan</investigator_full_name>
    <investigator_title>Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>retroperitoneal lymph node dissection</keyword>
  <keyword>testicular cancer</keyword>
  <keyword>testis cancer</keyword>
  <keyword>germ cell tumor</keyword>
  <keyword>PET scan</keyword>
  <keyword>Axumin</keyword>
  <keyword>teratoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Endodermal Sinus Tumor</mesh_term>
    <mesh_term>Choriocarcinoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Retroperitoneal Neoplasms</mesh_term>
    <mesh_term>Testicular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

